The so-called―Flash Crash‖ was a brief period of extreme market volatility on May 6, 2010.
That day, the Dow Jones Industrial Average (DJIA) fell by 998.5 points within seconds, …

Background At the primary data cut-off, the ALUR study demonstrated significantly improved
progression-free survival (PFS) and central nervous system (CNS) objective response rate (…

Competition for order flow is widely documented for US markets, but is a relatively new
phenomenon in European equities trading. Only with the Markets in Financial Instruments …

Background The ALUR (NCT02604342) primary analysis (cut-off January 2017) demonstrated
improved efficacy and safety with alectinib versus chemotherapy in patients with ALK+ …

The Balanced Scorecard (BSC) is a well-established framework for the management of a
company as it integrates financial and non-financial perspectives. Little attention has been …

Background: Alectinib has shown central nervous system (CNS) activity in phase II trials of
previously treated ALK+ NSCLC. We report CNS efficacy data from the phase III ALUR study (…

With the Markets in Financial Instruments Directive in effect since November 2007, new
trading venues have emerged in European equities trading, among them Chi-X. This paper …

Background Alectinib demonstrated superior efficacy versus chemotherapy in ALK+ NSCLC
after crizotinib failure (ALUR; NCT02604342). We present PROs and safety in the ITT …

This article describes the results of the study" MiFID-The perspective of European execution
venues", which was conducted among 33 European execution venues in the third quarter of …

This study sheds light on the resiliency of competing electronic order-driven markets by
investigating the time path of liquidity after a large endogenous shock by means of an intra-day …